Findings published in JAMA Neurology “showed that each added year of life does not lead to an increased prevalence of ADP, unlike cerebrovascular disease.” However age and APOE genotype are the strongest known amyloid risk factors. It was also found that intellectual enrichment was not a significant predictor of amyloid or AD-pattern neurodegeneration. “It has been shown that the APOE ε4 is related to amyloid but not related to tau pathology or AD-pattern neurodegeneration after accounting for an individual’s clinical status,” according to information cited in the article, aside from APOE genotype only midlife dyslipidemia was associated with amyloid deposition. Absence of the APOE ε4 allele may act as a protective factor to amyloid by delaying patient age at onset and slowing rate of accumulation.
Ozone therapy is a recognized anti-aging treatment that helps to lower blood pressure and gets more oxygen to the brain.
We recognize elevated heavy metals that cross the blood brain barrier as risk factors for Alzheimer disease. We test and treat heavy metal toxicity with I.V. ozone chelation therapy. It's safe, effective, advanced treatment that prevents further damage. All ozone and I.V. nutrient therapies are MD ordered in NYS.
Second Nature Care Better Brain Health.
1. Which of the following statements is/are TRUE regarding Alzheimer disease pathophysiology (ADP) and amyloid?
2. In study findings, intellectual enrichment was a significant predictor of __________.
3. APOE ε4 is related to __________, after accounting for patient clinical status.
4. According to study findings, __________ was NOT a significant predictor of amyloid deposition.
5. Absence of the APOE ε4 allele may act as a protective factor to amyloid by __________.
Check your answers below!
1. A. Age is one of the strongest amyloid risk factors
2. D. None of the Above
3. B. Amyloid
4. B. Cardiac and metabolic conditions (CMCs)
5. C. A or B
For complete information, see:
Vemuri P, Knopman DS, Lesnick TG, et al. Evaluation of amyloid protective factors and Alzheimer disease neurodegeneration protective factors in elderly individuals. [Published online ahead of print April 17, 2017]. JAMA Neurol. Accessed May 8, 2017.